Peptide LocalCompare price, evidence & access
Search /Compare vendors
Locations/South Africa/CagriSema
Purchase and availability checkCagriSema in South Africa

Can you buy CagriSema in South Africa?

No legitimate South African retail purchase is established by the current records. CagriSema remains an investigational fixed-dose combination, and a United States regulatory submission does not establish South African authorization or supply.

Direct answers →Open official records →Open the interactive status check
Evidence lane
CagriSema clinical identity and South Africa product verification
Destination
South Africa
Source records
3
Reviewed
24 July 2026
ByPeptide Local Editorial DeskUpdated 24 July 2026How we review
Direct answers

What this exact search can and cannot establish.

Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.

01

Can you buy CagriSema in South Africa?

No legitimate South African retail purchase is established by the current records. CagriSema remains an investigational fixed-dose combination, and a United States regulatory submission does not establish South African authorization or supply. A same-name online listing cannot inherit Novo Nordisk's clinical evidence or regulatory identity. Search SAHPRA for the exact product, presentation, authorization holder, and current status, then verify the seller and claimed supply route separately before interpreting any commercial offer.

02

Which official records should be checked for CagriSema in South Africa?

Resolve the exact identity of CagriSema through REDEFINE 1 Phase 3 study - NCT05567796 from ClinicalTrials.gov. Then search Medicines Online Directory from South African Health Products Regulatory Authority for the destination product record and Pharmaceutical establishment licensing from South African Health Products Regulatory Authority for the seller, establishment, or supply route in South Africa. A match in one record does not replace the other two checks.

03

Does an online listing prove CagriSema is authorized or available in South Africa?

No. A page using the name CagriSema, local currency, a domestic delivery claim, or a familiar package image is only a lead. This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status. For South Africa, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.

Live trial footprint

CagriSema clinical trials in South Africa

7 study records currently list 68 locations in this country, including 0 locations individually marked Recruiting.

Registry update: 24 July 2026
Study records
7
Listed locations
68
Recruiting locations
0
Records with local recruiting sites
0
NCT07564414
Study-wide statusRecruiting

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Listed locations
15
Recruiting locations
0
Registry update
2026-07-08
NCT05567796
Study-wide statusActive, not recruiting

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

Listed locations
9
Recruiting locations
0
Registry update
2026-07-17
NCT05669755
Study-wide statusActive, not recruiting

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Listed locations
20
Recruiting locations
0
Registry update
2026-07-17
NCT07357766
Study-wide statusWithdrawn

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

Listed locations
7
Recruiting locations
0
Registry update
2026-07-09
NCT06065540
Study-wide statusCompleted

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Listed locations
6
Recruiting locations
0
Registry update
2026-07-08
NCT06221969
Study-wide statusCompleted

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Listed locations
6
Recruiting locations
0
Registry update
2026-04-22
Continue the exact comparison

Related country and compound records.

Compare another tracked name in South Africa, or keep CagriSema fixed and change the destination within Middle East and Africa. The identity, product, and seller checks remain separate.

Continue the exact comparison

CagriSema in Middle East and Africa

CagriSema across 42 countries
Identity before availability

A name alone cannot establish a local verdict.

Novo Nordisk states that CagriSema was submitted to the US FDA in December 2025 and that an FDA decision is anticipated by late 2026. That US review does not establish South African authorization or supply. SAHPRA's registered-product service is the official route for checking an exact South African product record. No compound-specific South African authorization finding is attached here, so an online offer cannot inherit the sponsor program's identity, evidence, or regulatory status.

Primary identity source: REDEFINE 1 Phase 3 study - NCT05567796 / ClinicalTrials.gov ↗
Three-record verification path

Identity. Product. Seller or supply.

A credible result must keep these separate. The official links answer different questions and should be checked in sequence.

REDEFINE 1 Phase 3 study - NCT05567796

REDEFINE 1 Phase 3 study - NCT05567796 is maintained by ClinicalTrials.gov. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open REDEFINE 1 Phase 3 study - NCT05567796 ↗

Medicines Online Directory

Medicines Online Directory is maintained by South African Health Products Regulatory Authority. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Medicines Online Directory ↗

Pharmaceutical establishment licensing

Pharmaceutical establishment licensing is maintained by South African Health Products Regulatory Authority. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Pharmaceutical establishment licensing ↗
South Africa / Country guide

South Africa market context.

SAHPRA currently names several peptides promoted through online platforms, social media, gyms, wellness centres, and informal suppliers. A product name, research label, local address, or laboratory report cannot replace the exact medicine and establishment records.

  • SAHPRA's current warning says unregistered peptide products are being unlawfully marketed in South Africa and names multiple peptides commonly promoted online.
  • The Medicines Online Directory covers SAHPRA-registered over-the-counter and prescription medicines and supports searches by medicine name or active ingredient.
  • SAHPRA's pharmaceutical register includes active, revoked, suspended, cancelled, and permanently closed establishments, so current status and legal identity both matter.
Destination checklist

Repeat the country checks before comparing any offer.

The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.

01

Read the peptide-specific warning

Start with SAHPRA's public peptide page, which specifically addresses BPC-157, TB-500, CJC-1295, ipamorelin, PT-141, AOD-9604, Selank, Semax, Melanotan II, and certain GLP-1 products.

02

Search the medicine record

Use SAHPRA's Medicines Online Directory and registered-health-product resources to match the exact medicine, active ingredient, holder, pack, and current information instead of relying on a shared peptide name.

03

Verify the operating establishment

Check SAHPRA's pharmaceutical establishment register for the named manufacturer, importer, wholesaler, or distributor. A product entry and an establishment licence answer separate questions.

Primary evidence

Audit every source used by this page.

Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.

01
NCT05567796: A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightClinicalTrials.gov
02
SAHPRA registered product information serviceSouth African Health Products Regulatory Authority
03
Pharmaceutical establishment licensingSouth African Health Products Regulatory Authority
04
CagriSema REDEFINE 4 and FDA review updateNovo Nordisk
05
Peptide Products public informationSouth African Health Products Regulatory Authority
06
CagriSema study search in South AfricaClinicalTrials.gov
07
NCT07564414: A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightClinicalTrials.gov
08
NCT05669755: REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsClinicalTrials.gov
09
NCT07357766: A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightClinicalTrials.gov
10
NCT06065540: A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorClinicalTrials.gov
11
NCT06221969: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorClinicalTrials.gov
Audit and handoff

Keep the exact record attached.